Efficacy and safety of asciminib in chronic myeloid leukemia in chronic phase (CML-CP): Interim results from the phase 2 ASC2ESCALAT trial in the cohort of patients (pts) after 1 prior tyrosine kinase inhibitor (TKI) Meeting Abstract


Authors: Atallah, E. L.; Levy, M. Y.; Koller, P. B.; Sasaki, K.; Tantravahi, S. K.; Andorsky, D.; Bremer, C. T.; Zeidner, J. F.; Luskin, M. R.; Munker, R.; Yang, D.; Laine, D.; Sabo, J.; Gu, E.; Mauro, M. J.; Cortes, J. E.
Abstract Title: Efficacy and safety of asciminib in chronic myeloid leukemia in chronic phase (CML-CP): Interim results from the phase 2 ASC2ESCALAT trial in the cohort of patients (pts) after 1 prior tyrosine kinase inhibitor (TKI)
Meeting Title: 66th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 144
Issue: Suppl. 1
Meeting Dates: 2024 Dec 7-10
Meeting Location: San Diego, CA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2024-11-05
Start Page: 479
End Page: 480
Language: English
ACCESSION: WOS:001415654100029
DOI: 10.1182/blood-2024-200717
PROVIDER: wos
Notes: Meeting Abstract -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Michael John Mauro
    269 Mauro